LENZ Therapeutics, Inc.
LENZ- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001815776
No open-market purchases or sales by LENZ Therapeutics, Inc. insiders were filed in the last 90 days; 145 institutions reported holding it in 13F filings for Q2 2026, worth $197.3M in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding LENZ Therapeutics, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 65 | 1 | 78 | +14 |
| Shares | 18.9M | 960.0K | 18.7M | +782.1K (+4.4%) |
| Value | $327.0M | $16.6M | $444.8M | +$134.4M (+43.3%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (23)
Institutions that held LENZ Therapeutics, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
Sold out (9)
Institutions that held LENZ Therapeutics, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Board of Trustees of The Leland Stanford Junior University | 100,438 | $1.74M |
| Prosight Management, LP | 59,542 | $1.03M |
| Jump Financial, LLC | 22,611 | $390.9K |
| Marshall Wace, LLP | 22,554 | $390.0K |
| Bridgeway Capital Management, LLC | 21,920 | $379.0K |
| Deerfield Management Company, L.P. (Series C) | 17,353 | $300.0K |
| Engineers Gate Manager LP | 14,654 | $253.4K |
| Prudential Financial Inc | 12,435 | $215.0K |
| Lazard Asset Management LLC | 12 | $0 |
Not filed for Q3 2024 yet (1)
Institutions that held LENZ Therapeutics, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 960,044 | $16.6M |